PMC:7534795 / 48345-48558 JSONTXT

{"project":"LitCovid-PD-CHEBI","denotations":[{"id":"T18","span":{"begin":23,"end":32},"obj":"Chemical"},{"id":"T19","span":{"begin":33,"end":42},"obj":"Chemical"}],"attributes":[{"id":"A27338","pred":"chebi_id","subj":"T18","obj":"http://purl.obolibrary.org/obo/CHEBI_31781"},{"id":"A77827","pred":"chebi_id","subj":"T19","obj":"http://purl.obolibrary.org/obo/CHEBI_45409"}],"text":"Moreover, about 14% of lopinavir–ritonavir recipients were unable to complete the full 14-day course of administration due primarily to the adverse events including the risks of QT prolongation (Cao et al., 2020)."}

{"project":"LitCovid-sentences","denotations":[{"id":"T409","span":{"begin":0,"end":213},"obj":"Sentence"}],"namespaces":[{"prefix":"_base","uri":"http://pubannotation.org/ontology/tao.owl#"}],"text":"Moreover, about 14% of lopinavir–ritonavir recipients were unable to complete the full 14-day course of administration due primarily to the adverse events including the risks of QT prolongation (Cao et al., 2020)."}

{"project":"2_test","denotations":[{"id":"33031856-32187464-84038893","span":{"begin":207,"end":211},"obj":"32187464"}],"text":"Moreover, about 14% of lopinavir–ritonavir recipients were unable to complete the full 14-day course of administration due primarily to the adverse events including the risks of QT prolongation (Cao et al., 2020)."}

{"project":"LitCovid-PubTator","denotations":[{"id":"1482","span":{"begin":23,"end":42},"obj":"Chemical"},{"id":"1498","span":{"begin":178,"end":193},"obj":"Disease"}],"attributes":[{"id":"A1482","pred":"tao:has_database_id","subj":"1482","obj":"MESH:C558899"},{"id":"A1498","pred":"tao:has_database_id","subj":"1498","obj":"MESH:D008133"}],"namespaces":[{"prefix":"Tax","uri":"https://www.ncbi.nlm.nih.gov/taxonomy/"},{"prefix":"MESH","uri":"https://id.nlm.nih.gov/mesh/"},{"prefix":"Gene","uri":"https://www.ncbi.nlm.nih.gov/gene/"},{"prefix":"CVCL","uri":"https://web.expasy.org/cellosaurus/CVCL_"}],"text":"Moreover, about 14% of lopinavir–ritonavir recipients were unable to complete the full 14-day course of administration due primarily to the adverse events including the risks of QT prolongation (Cao et al., 2020)."}